- Drug discovery services
- Our technology
- Your benefits
- Resources & Webinars
- News & Events
- About us
Feb 6 2023
'PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo'.
This poster showcases Inovotion's results in Immuno-Oncology (IO), using its chicken embryo model.
For IO drug development, a pertinent preclinical model is needed for efficient preclinical evaluation of new drugs.
The commonly used mouse model presents numerous drawbacks, including ethical constraints, time, and cost, which severely limit IO drug development. An alternative, 3Rs-compliant, fast, and pertinent in vivo model for IO research is needed. For this, Inovotion has carried out an anti-tumor efficacy study of programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors based on the Chicken Chorioallantoic Membrane (CAM) assay, to assess the pertinence of its chicken embryo model, and its use for IO drug discovery.
In this study, we first investigated the status of the chicken embryo's immune system at a late development stage and checked in vitro the interaction between pembrolizumab and chicken immune T cells. We then validated the potency of the chicken embryo model as an in vivo IO testing model using clinically approved human PD-1/PD-L1 checkpoint inhibitors and showed the absence of toxicity of these IO agents in ovo.
Many thanks to the co-authors: Dr Yan Wang, Dr Xavier Rousset, Dr Chloé Prunier, Dr Paul Garcia, Emilien Dosda, Estelle Leplus, and Dr Jean Viallet.